A bioreactor is a vessel designed to grow living cells, tissues, or microorganisms under carefully controlled conditions. It works by managing temperature, pH, oxygen levels, and nutrient supply to keep biological systems alive and productive. These controlled environments show up across a surprisingly wide range of industries, from brewing beer to growing replacement cartilage for damaged joints.
How a Bioreactor Works
At its simplest, a bioreactor is a container where a biological reaction takes place. What separates it from, say, a bucket of water with some yeast in it is precision. Sensors continuously track dissolved oxygen, acidity, temperature, and nutrient concentrations. Automated systems adjust these variables in real time to keep the organisms inside healthy and productive. Agitation (stirring or bubbling air) ensures nutrients reach every cell evenly and waste products don’t build up in pockets.
The biological systems growing inside can be bacteria, yeast, fungi, animal cells, plant cells, algae, or even slices of living tissue. What they all share is a need for a stable environment. Left uncontrolled, rising acidity from metabolic waste or a dip in oxygen can kill a culture in hours. The bioreactor’s job is to prevent that.
Pharmaceutical and Antibody Production
The biggest commercial use of bioreactors today is manufacturing biological drugs. Monoclonal antibodies, which treat cancers, autoimmune diseases, and infections, are proteins too complex to synthesize chemically. Instead, manufacturers grow engineered mammalian cells in large stirred-tank bioreactors and harvest the antibodies those cells secrete. The global bioreactor market was valued at $13.8 billion in 2025 and is projected to reach $38.9 billion by 2035, driven largely by demand for these therapies.
Vaccines follow a similar path. Viral components or proteins are produced in cell cultures housed inside bioreactors, then purified and formulated into doses. The scale can be enormous. Stainless steel bioreactors in pharmaceutical plants hold up to 20,000 liters, and a single facility may run dozens of them.
Wastewater Treatment
Municipal sewage plants are, in a sense, giant bioreactors. Membrane bioreactors combine physical filtration with microbial biodegradation to strip pollutants from water. Communities of bacteria, fungi, algae, and yeast break down organic matter, neutralize toxic compounds, and convert harmful nitrogen into harmless gas. Specific groups of bacteria handle specific jobs: sulfate-reducing bacteria process sulfur compounds, methanotrophs consume dissolved methane, and algal species like Chlorella pull excess nitrogen and phosphorus from the water.
Industrial wastewater poses tougher challenges. Textile factories discharge chemical dyes, oil refineries release hydrocarbons, and food processors dump high concentrations of organic waste. Bioreactors tailored to each waste stream use carefully selected microbial communities. Certain yeast species can degrade synthetic dyes, while cyanobacteria have proven effective against industrial chemical residues. The principle is the same in every case: create the right conditions for the right organisms, and biology does the cleanup work.
Growing Meat Without Animals
Cultured meat relies on bioreactors to grow animal muscle cells outside the body. The process starts with a small biopsy from a living animal. Those cells are placed in progressively larger bioreactors, multiplying at each stage until they fill a production vessel. One leading concept envisions a final bioreactor of about 20 cubic meters producing 2 to 3 tons of cell mass per batch.
Scaling up remains the core challenge. Economic modeling suggests an optimal production bioreactor size of around 50 cubic meters. Go bigger, and carbon dioxide buildup inside the tank limits how densely cells can grow, canceling out the savings of a larger vessel. A single facility would ideally run about 24 production bioreactors before the cost of maintaining the required sterile environment starts outpacing the added output. These constraints borrow directly from decades of pharmaceutical bioreactor engineering, adapted for food-grade production.
Animal-Free Dairy and Egg Proteins
Precision fermentation uses bioreactors to produce specific animal proteins without raising animals. Engineered yeast or bacteria serve as tiny cell factories, programmed to manufacture whey protein, casein, or egg-white proteins. The microorganisms are fed sugar in a bioreactor, and they secrete the target protein as they grow. After harvesting, the protein is purified and used in food products that taste and function like their animal-derived counterparts. This approach is already commercial for some dairy proteins and is expanding into collagen, gelatin, and flavoring compounds.
Biofuel From Algae
Photobioreactors are transparent vessels that expose algae or cyanobacteria to light, allowing them to photosynthesize and accumulate oils that can be converted into biodiesel. These systems use thin, flat panels or tubes to maximize the light reaching each cell. Under controlled conditions, green microalgae convert light energy into biomass at rates of 0.6 to 1.0 grams of dry matter per unit of light absorbed, with some cyanobacteria reaching up to 1.5 grams. Current systems capture roughly 40 to 50% of available light energy as usable biomass, leaving significant room for improvement but already demonstrating that algae can produce far more oil per acre than traditional crop-based biofuels.
Tissue Engineering and Organ Repair
In regenerative medicine, bioreactors grow living tissue on three-dimensional scaffolds. A surgeon might seed a biodegradable scaffold with a patient’s own cells, then place the construct in a bioreactor that applies mechanical forces mimicking the body’s natural environment. For bone repair, that means compression. For ligaments, it means cyclic stretching. For cartilage, fluid flow that gently shears the surface.
These mechanical signals aren’t cosmetic. Research has shown that applying dynamic fluid flow to a seeded scaffold produces a uniform distribution of cells throughout the construct, while direct mechanical strain can steer stem cells toward becoming ligament tissue rather than bone or cartilage. Bioreactors can also expand populations of blood-forming stem cells for transplant patients or maintain living tissue as a bridge while a patient awaits organ transplantation.
Common Bioreactor Types
The stirred-tank bioreactor is the workhorse of the industry. A motor-driven impeller mixes the contents while sensors track conditions and automated systems adjust them. This design dominates pharmaceutical manufacturing because it scales predictably and decades of engineering data back it up.
Airlift bioreactors replace the mechanical impeller with rising air bubbles that circulate the liquid. They generate less physical stress on fragile cells and cost less to build and operate, making them attractive for processes where gentle mixing is enough. Photobioreactors, designed for light-dependent organisms, prioritize surface area and transparency over volume. Wave-type bioreactors rock a flexible bag back and forth to mix its contents, and they’re popular for smaller-scale or research applications.
Single-Use vs. Stainless Steel
Traditional stainless steel bioreactors are built to last decades but require extensive cleaning and sterilization between batches. Single-use bioreactors replace the vessel’s interior with a pre-sterilized disposable plastic liner. They cost significantly less upfront, reduce water and energy consumption, and cut consumable costs by roughly 37% compared to stainless steel systems. They also lower the risk of cross-contamination between batches, which matters enormously when producing injectable drugs.
The tradeoff is size. Single-use systems currently top out at smaller volumes than their stainless steel counterparts. For manufacturers running high-volume, long-term production of a single product, stainless steel still makes economic sense. But for companies producing multiple products, scaling up new therapies, or building flexible facilities, single-use systems have become the default choice.
Batch, Fed-Batch, and Continuous Operation
Bioreactors run in three basic modes. In batch mode, everything goes in at the start, the organisms grow until nutrients run out, and the product is harvested. It’s simple but inefficient for high-value products. Fed-batch mode adds fresh nutrients over time without removing anything, extending the productive phase and increasing yield. This is the standard for most antibody manufacturing today.
Perfusion mode continuously feeds fresh nutrients in while drawing spent media and product out through a filter. The cells stay inside, but the product streams out in real time. This allows much higher cell densities and longer production runs. Emerging perfusion systems have shown the potential to reduce manufacturing costs by about 20% compared to conventional fed-batch processes, largely by getting more product out of smaller equipment.